Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Diastika Biotekindo TbkISX:CHEK -2.26%2 Net Current Asset Value is Rp0.00 as of . 20. GuruFocus rates ISX:CHEK with a GF Score™ of 2/100. The stock has 1 warning sign investors should review. Among 78 Medical Distribution companies, PT Diastika Biotekindo Tbk ranks worse than 1282050% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
PT Diastika Biotekindo Tbk's net current asset value per share for the quarter that ended in . 20 was Rp0.00.
The historical rank and industry rank for PT Diastika Biotekindo Tbk's Net Current Asset Value or its related term are showing as below:
ISX:CHEK's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Distribution industry.
Industry Median: 3.32 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PT Diastika Biotekindo Tbk (ISX:CHEK) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
PT Diastika Biotekindo Tbk Net Current Asset Value Related Terms
PT Diastika Biotekindo Tbk Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diastika Biotekindo Tbk Net Current Asset Value Chart
PT Diastika Biotekindo Tbk Annual Data
Trend
Net Current Asset Value
PT Diastika Biotekindo Tbk Semi-Annual Data
Net Current Asset Value
ISX:CHEK vs MCK, COR, CAH: Net Current Asset Value Comparison
For the Medical Distribution subindustry, PT Diastika Biotekindo Tbk's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Diastika Biotekindo Tbk Price-to-Net-Current-Asset-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Diastika Biotekindo Tbk's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where PT Diastika Biotekindo Tbk's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of Rp0.00 mean?
PT Diastika Biotekindo Tbk (ISX:CHEK) has a Net Current Asset Value of Rp0.00 as of . 20. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PT Diastika Biotekindo Tbk and its competitors. According to the industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 78 companies in the Medical Distribution industry.
Is PT Diastika Biotekindo Tbk's Net Current Asset Value too high?
PT Diastika Biotekindo Tbk's current Net Current Asset Value is Rp0.00. Based on the distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 78 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Diastika Biotekindo Tbk has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does PT Diastika Biotekindo Tbk's Net Current Asset Value compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 78 companies for Net Current Asset Value. This places PT Diastika Biotekindo Tbk in the lower half of its industry. The industry median Net Current Asset Value is 3.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Distribution company?
The median Net Current Asset Value among Medical Distribution companies is 3.32, based on 78 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PT Diastika Biotekindo Tbk and its competitors. For the Medical Distribution industry, the median Net Current Asset Value is 3.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Diastika Biotekindo Tbk's current Net Current Asset Value is Rp0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Diastika Biotekindo Tbk stock overvalued right now?
PT Diastika Biotekindo Tbk (ISX:CHEK) has a current Net Current Asset Value of Rp0.00. The current Net Current Asset Value is Rp0.00. PT Diastika Biotekindo Tbk's overall GF Score™ is 2/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For PT Diastika Biotekindo Tbk (ISX:CHEK), the current Net Current Asset Value is Rp0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressJalan Rawagelam V, Kawasan Industri Pulogadung, Block L, No. Kav 11-13, Gedung Etana Lantai 3, Desa/Kelurahan Jatinegara, Kec. Cakung, Kota Adm. Jakarta Timur, Jakarta, IDN, 13930
PT Diastika Biotekindo Tbk is engaged in providing medical and laboratory equipment solutions in Indonesia. It is engaged in the wholesale trading of laboratory equipment, pharmaceutical products, and medical devices for human use. The company is also involved in wholesale trading of radioactive substances and ionizing radiation generators, and undertakes activities related to the testing and/or calibration of medical devices, as well as the inspection of healthcare facilities and infrastructure. Its product offerings mainly include devices like hematology analyzer, pipette, hemoglobin testing system, etc. The company's operating segments are: Diagnostics Group, which generates the maximum revenue, and Life Sciences Group. Geographically, all of its revenue is derived from Indonesia.
2GF Score
Get the complete analysis for ISX:CHEK
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:CHEK has been successfully added to your 
